Abiopharma

Financial Statements as of June 30, 2026

Initial Details of the Corporation’s Securities and the Corporation’s Capital

Initial Details of Accountant

Initial Details relating to Directors and Senior Management

Initial Details relating to Major Shareholders

Initial Memorandum and Articles Report

General Announcement: Net Asset Value ("NAV") as of 12 August 2026

Robinhood Ventures Fund II (RVII) Announces Pricing of Initial Public Offering

Dormant shares – change in the number of shares

Q2/semi-annual report for 2026